



A call for collaborative Medicinal Chemistry projects 2021-2022

EOI due April 30th 2021

The **ATMCF** provides Australian researchers with an opportunity to:

- access subsidised medicinal chemistry
- access the **Therapeutic Innovation Australia (TIA) Pipeline Accelerator** for further cost reductions
- work with a team of medicinal chemists who have a proven track record in drug discovery and commercialisation outcomes

A short EOI template is available upon request.

The ATMCF is a national drug discovery capability that applies medicinal chemistry expertise to translate biomedical research towards clinical relevance. Facilitated by Therapeutic Innovation Australia (TIA), and based at The Monash Institute of Pharmaceutical Sciences (MIPS), Parkville, the ATMCF collaborates with researchers to identify and synthesize bioactive compounds (small molecules) which are optimized through medicinal chemistry against a range of potency, selectivity and pharmacokinetic criteria.

Do you require assistance in finding the right biologically active compound for your target or disease of interest? Not sure that you have adequate funding for a medicinal chemistry project? Talk to us. We will work with you, and our partners, to discuss shared risk options and/or other funding opportunities for cost leveraging on your project.

Director: Professor Jonathan Baell

Manager: Dr Leanne Hawkey

Contact: leanne.hawkey@monash.edu